President, Chief Executive Officer · Ayala Pharmaceuticals, Inc. (ADXS)

Kenneth Berlin

A named executive officer of Ayala Pharmaceuticals in every fiscal year CompBrief holds from FY2021 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$703,768

Salary $643,427Stock awards $0

FY2021: $625,398

1st of 3 named executive officers at Ayala Pharmaceuticals by FY2022 total.

3 named officers on file for Ayala Pharmaceuticals, FY2022

Kenneth Berlin’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Ayala Pharmaceuticals’s whole pay program stands against its peers

  • Ayala Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ADXS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 23, 2023 (DEF 14A).

Free

Get Kenneth Berlin’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Kenneth Berlin compensation by year

Ayala Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Ayala Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022
Salary$569,670$643,427
Bonus$0$0
Stock awards$0$0
Option awards$0$0
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$55,728$60,341
Total$625,398$703,768

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Ayala Pharmaceuticals, Inc. DEF 14A filed June 23, 2023, accession 0001493152-23-022199, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Ayala Pharmaceuticals, Inc. filed document, accession 0001493152-23-022199. Every figure is read from that document and cited to the page and table it appears in. Filed June 23, 2023.

$625K
$704K
FY21
FY22
SalaryAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
Option208—$52.80

Per the Outstanding Equity Awards at Fiscal Year-End table in Ayala Pharmaceuticals, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments Ayala Pharmaceuticals discloses, by trigger · FY2022
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$870,144$0$26,038$1,279,045
Change in control and involuntary termination$2,157,996$0$41,660$2,582,519
Death$0$0$0$382,863
Disability$870,144$0$26,038$1,279,045
Involuntary for cause$0$0$0$0
Voluntary resignation$0$0$0$0

Per the Potential Payments Upon Termination or Change in Control table in Ayala Pharmaceuticals, Inc.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.

Ayala Pharmaceuticals’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Kenneth Berlin · this pagePresident, Chief Executive Officer$703,768
Andres GutierrezSenior VP, Chief Medical Officer$533,627
Igor GitelmanInterim Chief Financial Officer$342,209

Board service

Ayala Pharmaceuticals board · FY2022

How this board is paid

Company policy: Ayala Pharmaceuticals pays directors a $50,000 cash retainer. As stated in Ayala Pharmaceuticals's FY2022 proxy.

The full Ayala Pharmaceuticals compensation record

free company brief

This page is one person within Ayala Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Ayala Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kenneth Berlin's compensation dossier · One-time report. No refunds.